“We will work to make Rybrevant, which had been first approved to treat EGFR exon 20 insertion mutations, the No.1 option for lung cancer patients in Korea.”

Janssen Korea expressed so at the press conference that was held on the 23rd to celebrate the launch of Rybrevant in Korea.

Rybrevant (amivantamab) received marketing authorization from the Ministry of Food and Drug Safety in February and was officially released this month. As the first and only dual inhibitor that targets both the EGFR exon 20 insertion mutation and MET, the drug is approved for use in patients whose disease has progressed during or after platinum-based chemotherapy treatment.

According to the CHRYSAL